info@brg.care WhatsApp Support
EN | RU | ID Portal
Structural Advantage Analysis 2026

Why .China

A data-driven assessment of global medical competitiveness: where clinical experience density meets rapid technological scale.

Global Benchmarks

China provides elite outcomes at 10-30% of US/EU costs. Time is clinical value: Tier-1 centers offer imaging in 48 hours, bypassing months of wait typical in OECD regions.

Market MRI Wait Cardiac Stent CAR-T Therapy
USA / EU 40-80+ Days $35k - $300k $200k - $1M
Singapore 7-14 Days $25k - $45k $150k - $300k
China (3A) < 2 Days $4k - $11k $40k - $80k
48H Diagnostic Turnaround

Rapid Tech Implementation

China leads in the deployment of **Da Vinci robotics** and **AI diagnostics**. Our engineering capacity allows CAR-T and PET-MR technologies to reach clinical scale years ahead of other regions.

Global Hub for CAR-T Trials

Experience Density

Specialized MDTs deliver strategies within 48-72 hours. Leading surgeons perform 800+ annual procedures—3x Western averages.

800+ Surgeries / Yr
4.8M Oncology Cases

TCM Institutional Integration

TCM synergy accelerates post-op care through constitutional adjustment and acupuncture—a core institutional component unique to China.